Name | Value |
---|---|
Revenues | 0.0M |
Cost of Revenue | 0.3M |
Gross Profit | -0.3M |
Operating Expense | 13.4M |
Operating I/L | -13.4M |
Other Income/Expense | 0.9M |
Interest Income | 1.5M |
Pretax | -12.5M |
Income Tax Expense | -0.9M |
Net Income/Loss | -11.6M |
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision oncology medicines. Their lead product, CYT-0851, is a novel, oral, once-daily, small molecule drug candidate currently in Phase I/II clinical trials for monotherapy and combination therapy in solid tumors and hematologic malignancies. Additionally, the company is developing CYT-1853, a preclinical drug for the same indications. By focusing on the development and commercialization of these next-generation precision oncology medicines, Cyteir Therapeutics aims to generate revenue through the successful advancement and eventual commercialization of their drug candidates.